GrayMatters Health develops digital self-neuromodulation therapies for mental disorders. They are the first to use advanced statistical models to develop biomarkers of brain-mechanism-specific activity associated with mental disorders. The company’s products use these biomarkers with an interactive audio/visual interface to help patients regain control over the relevant brain activity.
- Invested amount
EUR 2 000 000